denosumab

noun

den·​o·​su·​mab ˌden-ˈō-sə-ˌmab 

: a drug that is a genetically engineered monoclonal antibody that reduces bone resorption and increases bone mass by inhibiting osteoclast formation and function and that is administered by injection to prevent fractures associated with osteoporosis and malignant tumors of bone and to treat hypercalcemia associated with various cancers

Note: Denosumab is marketed under the trademarks Prolia and Xgeva.